ReviewCurrent opinion in immunology2021
Supply and delivery of vaccines for global health.
Review in Current opinion in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Progress, impacts and lessons from market shaping in the past decade: a systematic review.Frontiers in public health · 2025Pooled it
- The power of powerful others: health locus of control and vaccination behavior in rural Namibian pastoralists.BMC global and public health · 2026Article
- Enhancing vaccine stability in transdermal microneedle platforms.Drug delivery and translational research · 2025Review
- HPV Vaccine Hesitancy and Uptake: A Conceptual Analysis Using Rodgers' Evolutionary Approach.Journal of advanced nursing · 2025Review
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Context dependent preferences in prestige bias learning about vaccination in rural Namibian pastoralists.Social science & medicine (1982) · 2024Article
- Vaccine hesitancy among physicians: a qualitative study with general practitioners and paediatricians in Austria and Germany.BMJ open · 2024Article
- Vaccine value profile for cytomegalovirus.Vaccine · 2023Article
- Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study.BMC medicine · 2023Observational
- Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study.Pathogens and global health · 2023Article
- [Evaluation of COVID-19 vaccination programs in South America].Ethic@ : an international journal for moral philosophy = Revista internacional de filosofia da moral · 2023Article
- Mitigating the effects of climate change on human health with vaccines and vaccinations.Frontiers in public health · 2023Review
- A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development.Human vaccines & immunotherapeutics · 2022Review
- The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize.Molecular therapy. Nucleic acids · 2022Review
- Article
- Management of COVID-19 vaccines cold chain logistics: a scoping review.Journal of pharmaceutical policy and practice · 2022Article
- Review
- Nanodelivery of nucleic acids.Nature reviews. Methods primers · 2022Article
- Development of an OralVaccines · 2022Article
- Energy, environmental, economic and social equity (4E) pressures of COVID-19 vaccination mismanagement: A global perspective.Energy (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines developed in high-income countries have been enormously successful in reducing the global burden of infectious diseases, saving perhaps 2.5 million lives per year, but even for successful cases, like the rotavirus vaccine, global implementation may take a decade or more. For unincentivized vaccines, the delays are even more profound, as both the supply of a vaccine from developing country manufacturers and vaccine demand from countries with the high disease burdens have to be generated in order for impact to be manifest. A number of poverty-associated infectious diseases, whose burden is greatest in low-income and middle-income countries, would benefit from appropriate levels of support for vaccine development such as Group A Streptococcus, invasive non-typhoid salmonella, schistosomiasis, shigella, to name a few. With COVID-19 vaccines we will hopefully be able to provide novel vaccine technology to all countries through a unique collaborative effort, the COVAX facility, led by the World Health Organization (WHO), Gavi, and the Coalition for Epidemic Preparedness Innovations (CEPI). Whether this effort can deliver vaccine to all its participating countries remains to be seen, but this ambitious effort to develop, manufacture, distribute, and vaccinate 60-80% of the world's population will hopefully be a lasting legacy of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.